BoneChat #146 - Raising Capital, Protecting Equity, Dilution & Staying Lean

Orthopedic founders and operators talk through the real math of early fundraising: how much to raise, what equity to give up, and how not to end up a hired CEO of your own company. Tiger Buford hosts Kyle Lappin, Todd Martens, Eric Lange, and Raymond Cloutier (NovaProach) for an open discussion on startup capital in spine and orthopedics. They cover founder ownership vs. professional CEOs, friends-and-family and angel money vs. VCs, milestone tranches, debt, distribution partnerships, and why “half a grape vs. a tenth of a watermelon” is a fight every founder has heard. They also get into patents that no longer protect the way they used to, why big-company hires often fail in startups, and lean models that reached cash flow fast (Osseo’s great-toe pins, a self-funded carpal tunnel kit). Plus NASS in San Antonio, Spine Venture Village, and why surgeons are skipping the big meetings. Topics: Why most executives are open to a better opportunity Battle-tested leaders and the Danek near-death stories Patents, infringement, and why broad claims are gone How much equity a founder should keep (and why 2–5% kills motivation) Seed rounds, convertible notes, and not boiling the ocean Good money vs. bad money, including strategic “partnerships” Crowdfunding that worked (and one that only broke even) Scrappy path to break-even vs. the big-company playbook Ramp, Mercury, and a simple digital QMS before you buy an EQMS If you’re building or funding an orthopedic or spine company, this is the unscripted version of the capital conversation.